ONO-7429-01:A phase 1 study of ONO-7429 in participants with unresectable advanced or recurrent solid tumors

ONO-7429-01:A phase 1, open-label, dose escalation study to investigate the safety and tolerability of ONO-7429 in participants with unresectable advanced or recurrent solid tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2041260054

Enrollment

Registered

2026-06-08

Start date

2026-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced or recurrent solid tumors

Interventions

Administration of ONO-7429

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors. 2. Participants who are refractory or intolerant to standard therapy. 3. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1. 4. Participants with tumor tissue samples available for biomarker testing.

Exclusion criteria

Exclusion criteria: 1. Participants with a history or presence of severe hypersensitivity to any other antibody agents. 2. Participants with pericardial fluid, pleural effusion or ascites requiring treatment 3. Participants with uncontrolled tumor-related pain 4. Participants with severe peritoneal dissemination. 5. Participants with multiple primary cancers. 6. Participants with a history or presence of ILD or pulmonary fibrosis.

Design outcomes

Primary

Measure	Time frame
Tolerability, safety	—

Secondary

Measure	Time frame
Efficacy, Pharmacokinetics (PK), and Immunogenicity	—

Contacts

Public ContactSupport Desk JP

Ono Pharmaceutical Co.,LTD.

clinical_trial@ono-pharma.com+81-120278120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026